载有二硫的纳米颗粒抑制了前脂质细胞的长期增殖
Helen Yarimet Lorenzo-Anota1,2, José María Gómez-Cantú2, Eduardo Vázquez-Garza1
1Tecnologico de Monterrey, Institute for Obesity Research, Monterrey, México.
International journal of nanomedicine
|December 16, 2024
概括
聚-ε-caprolactone (PCL) 纳米粒子有效地将二硫 (DSF) 输送到脂肪组织中. 这种持续释放显示出对前脂肪细胞的选择性毒性,为治疗与肥胖有关的疾病提供了一个有希望的替代方案.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 迪苏尔菲拉姆 (DSF) 显示出降低胰岛素抵抗和体重增加的潜力.
- 由于DSF的不稳定性限制了其临床应用,因此需要一个稳定的输送系统.
- 脂肪组织在代谢疾病中的作用需要有针对性的治疗策略.
研究的目的:
- 开发和优化聚-ε-caprolactone (PCL) 纳米颗粒,用于持续地将二硫 (DSF) 输送到脂肪组织.
- 为了评估DSF装载的PCL纳米颗粒对脂肪组织细胞的体外影响.
- 评估纳米封装的DSF与免费的DSF相比的安全性和有效性.
主要方法:
- 装有DSF的多-ε-caprolactone (PCL) 纳米粒子是使用纳米沉方法合成的.
- 优化涉及不同的溶剂混合物和PCL:DSF比率,最佳条件被确定为乙/二甲混合物和2:1比率.
- 通过评估细胞活力,内化和亡来评估NP的毒性,对前脂质细胞,白状脂质细胞和巨细胞进行了评估.
主要成果:
- 优化的PCL-DSFNP表现出球形形态,粒子大小为~203nm,持续药物释放超过96小时.
- 脂肪细胞将NP内部化,而不会影响巨细胞和白状脂肪细胞的活力.
- 在暴露于NP时,预adipocytes显示活力降低,线粒体损伤和亡,类似于自由的DSF,但具有潜在的较轻的影响.
结论:
- PCL纳米粒子为持续的DSF输送到脂肪组织提供了可行的载体.
- 与自由的DSF相比,DSF的纳米封装显示出对前细胞的选择性细胞毒性,并可能减少副作用.
- 这些发现表明PCL-DSFNP是脂肪组织向治疗的有希望的治疗替代方案.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.


